English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 911537      Online Users : 912
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12655


    Title: Combination therapy of pulsed-wave ultrasound hyperthermia and immunostimulant OK-432 enhances systemic antitumor immunity for cancer treatment
    Authors: Li, TC;Liu, CC;Lee, YZ;Hsu, YH;Chiang, CF;Miaw, SC;Lin, WL
    Contributors: Institute of Biomedical Engineering and Nanomedicine
    Abstract: PURPOSE: In this study, we hypothesized that systemic antitumor immunity might be enhanced by combining pulsed-wave ultrasound hyperthermia (pUSHT) with OK-432 and that the induced antitumor immunity could confer protection against tumorigenesis. These hypotheses were tested in bilateral and rechallenged tumor models. MATERIALS AND METHODS: Bilateral and rechallenged tumor models were applied in the studies. In the bilateral tumor model, BALB/c mice were inoculated with CT26-luc tumor cells into both flanks. The tumors in the right flank were treated with four courses of pUSHT with or without OK-432. In the rechallenged tumor model, tumor cells were implanted into the right flank. Once formed, the tumors were treated with pUSHT with OK-432, followed by surgical resection. New tumor cells were then implanted into the contralateral flank. The antitumor response was evaluated by infiltrated immune cells and the severity of necrosis/apoptosis in tumors. RESULTS: In the bilateral tumor model, the tumor growth rate and growth activity of both treated (100% reduction) and untreated tumors (90.5% reduction) were significantly inhibited with the combination treatment compared with the sham control group, and the systemic anti-tumor effect was prolonged. The survival rate was significantly enhanced (sham control: 8 days; OK+pUSHT: >20 days). IFNgamma(+) CD4 (treated tumor: 8.6-fold; untreated tumor: 4-fold), IFNgamma(+) CD8 (treated tumor: 6.7-fold; untreated tumor: 2.6-fold) T-cell and NK-cell (treated tumor: 4-fold; untreated tumor: 2.5-fold) infiltration were increased in the combination group compared with the control group. In the rechallenged tumor model, new tumors failed to form for the combination treatment. CONCLUSION: This experimental study combining pUSHT and OK-432 explored a new therapeutic strategy for controlling colon cancer metastasis, and the results showed that the combination treatment may produce an effective anti-tumor immune response.
    Date: 2020-09-01
    Relation: International Journal of Radiation Oncology, Biology, Physics. 2020 Sep 1;108(1):140-149.
    Link to: http://dx.doi.org/10.1016/j.ijrobp.2020.04.021
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0360-3016&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000561895300016
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85087070677
    Appears in Collections:[其他] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB32339644.pdf13583KbAdobe PDF285View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback